Mannatech wins patent suit
This article was originally published in The Tan Sheet
Executive Summary
As result of litigation to protect its patented glyconutrient products Ambrotose complex and Advanced Ambrotose formulas, the Coppell, Texas-based dietary supplements marketer announces that the U.S. District Court for the Northern District of Texas entered a final judgment and permanent injunction against Boston Mountain Laboratories, banning the firm from making or selling certain products for the duration of several of Mannatech's U.S. patents. Specifically, Boston Mountain Labs cannot sell BML Glyconutrient Formula, Glyco-8 and Glycoessentials, among others. Last year, the firm won patent and trademark claims it brought against Glycobiotics International for its infringing product Glycomannan (1"The Tan Sheet" July 21, 2008)
You may also be interested in...
Mannatech patents prevail again
The U.S. District Court for the Northern District of Texas prohibits Green Life and Xiong Lo from making, selling or distributing products infringing certain of Mannatech's patents. The Coppell, Texas, firm said Dec. 18 Green Life and Xiong Lo had purchased the Glyco 8 supplement from Boston Mountain Labs, against which Mannatech already prevailed in a separate patent case (1"The Tan Sheet" Oct. 12, 2009, In Brief)
Mannatech prevails over Glycoproducts
A federal judge rules Glycomannan by Glycoproducts International infringed on multiple patents held by Coppell, Texas-based Mannatech, according to Mannatech. The ruling by the U.S. District Court for the Northern District of Texas also entered a broad permanent injunction against Riggins, Idaho-based Glycoproducts to make, use or sell Glycomannan in the U.S., Mannatech says July 11. Mannatech sought the injunction following a trial jury ruling that Glycoproducts had only infringed one of two patents for Mannatech's Ambrotose glyconutrient supplement (1"The Tan Sheet" June 16, 2008, In Brief)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.